Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

½Å»ý¾Æ ¾àµ¿Çаú ¾à¹°¿ä¹ý Pharmacokinetics and drug therapy in neonates

´ëÇѼҾÆÀÀ±ÞÀÇÇÐȸÁö 2017³â 4±Ç 1È£ p.5 ~ 11
Á¶ÇýÁ¤,
¼Ò¼Ó »ó¼¼Á¤º¸
Á¶ÇýÁ¤ ( Cho Hye-Jung ) 
°¡Ãµ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç

Abstract


Neonates include both full term and preterm infants up to 28 days of age. The heterogeneity and rapid physiologic change of neonates affect all aspects of pharmacokinetics such as absorption, distribution, metabolism, and elimination. This feature should be considered in determining the dose and regimen of drug therapy in neonates. However, the research on the safety and efficacy of specific drugs is limited due to ethical and technical issues. This review article focuses on the neonatal pharmacokinetics and the rationales of drug therapy in neonates based on findings of previous studies and empirical evidence.

Å°¿öµå

Bronchiolitis; Drug Administration Routes; Drug Therapy; Infants; Newborn; Pharmacokinetics

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed